Literature DB >> 22497875

High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.

George V Aslanidi1, Angela E Rivers, Luis Ortiz, Lakshmanan Govindasamy, Chen Ling, Giridhara R Jayandharan, Sergei Zolotukhin, Mavis Agbandje-McKenna, Arun Srivastava.   

Abstract

Phosphorylation of surface-exposed tyrosine residues negatively impacts the transduction efficiency of recombinant AAV2 vectors. Pre-treatment of cells with specific cellular serine/threonine kinase inhibitors also significantly increased the transduction efficiency of AAV2 vectors. We reasoned that site-directed mutagenesis of surface-exposed serine residues might allow the vectors to evade phosphorylation and thus lead to higher transduction efficiency. Each of the 15 surface-exposed serine (S) residues was substituted with valine (V) residues, and the transduction efficiency of three of these mutants, S458V, S492V and S662V, was increased by up to ≈ 20-fold in different cell types. The S662V mutant was efficient in transducing human monocyte-derived dendritic cells (moDCs), a cell type not readily amenable to transduction by the conventional AAV vectors, and did not induce any phenotypic changes in these cells. Recombinant S662V-AAV2 vectors encoding a truncated human telomerase (hTERT) gene were generated and used to stimulate cytotoxic T cells (CTLs) against target cells. S662V-AAV2-hTERT vector-transduced DCs resulted in rapid, specific T-cell clone proliferation and generation of robust CTLs, which led to specific cell lysis of K562 cells. These studies suggest that high-efficiency transduction of moDCs by serine-modified AAV2 vectors is feasible, which supports the potential utility of these vectors for future human DCs vaccine studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22497875      PMCID: PMC3356484          DOI: 10.1016/j.vaccine.2012.03.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors: 
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

Review 3.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

4.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.

Authors:  Hilda Petrs-Silva; Astra Dinculescu; Qiuhong Li; Seok-Hong Min; Vince Chiodo; Ji-Jing Pang; Li Zhong; Sergei Zolotukhin; Arun Srivastava; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

5.  An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells.

Authors:  George Aslanidi; Kenneth Lamb; Sergei Zolotukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-11       Impact factor: 11.205

6.  Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.

Authors:  W A Aldrich; C Ren; A F White; S-Z Zhou; S Kumar; C B Jenkins; D R Shaw; T V Strong; P L Triozzi; S Ponnazhagan
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

7.  Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.

Authors:  Mahendran Mahadevan; Yong Liu; Changxuan You; Rongcheng Luo; Hong You; Jawahar L Mehta; Paul L Hermonat
Journal:  Cancer Immunol Immunother       Date:  2007-03-14       Impact factor: 6.968

8.  Adeno-associated virus-mediated gene transfer.

Authors:  Arun Srivastava
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

9.  A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis.

Authors:  Li Zhong; Weihong Zhao; Jianqing Wu; Baozheng Li; Sergei Zolotukhin; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Mol Ther       Date:  2007-04-17       Impact factor: 11.454

Review 10.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more
  28 in total

1.  Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors.

Authors:  Shaoyong Li; Chen Ling; Li Zhong; Mengxin Li; Qin Su; Ran He; Qiushi Tang; Dale L Greiner; Leonard D Shultz; Michael A Brehm; Terence R Flotte; Christian Mueller; Arun Srivastava; Guangping Gao
Journal:  Mol Ther       Date:  2015-09-25       Impact factor: 11.454

2.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

3.  Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation.

Authors:  Yuan Wang; Chen Ling; Liujiang Song; Lina Wang; George V Aslanidi; Mengqun Tan; Changquan Ling; Arun Srivastava
Journal:  Hum Gene Ther Methods       Date:  2012-08       Impact factor: 2.396

4.  Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Authors:  Nishanth Gabriel; Sangeetha Hareendran; Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Ruchita Selot; Mansoor Hussain; Ramya Dhaksnamoorthy; Rekha Samuel; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-03-15       Impact factor: 2.396

5.  Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses.

Authors:  Chen Ling; Baozheng Li; Wenqin Ma; Arun Srivastava
Journal:  Hum Gene Ther Methods       Date:  2016-08       Impact factor: 2.396

6.  E2F-1 promotes DAPK2-induced anti-tumor immunity of gastric cancer cells by targeting miR-34a.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Li Li; Jia Chen; Xian-Wei Mo; Yu-Zhou Qin; Wen-E Wei; Hai-Quan Qin; Yuan Lin; Jian-Si Chen
Journal:  Tumour Biol       Date:  2016-10-04

Review 7.  Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases.

Authors:  Kenneth I Berns; Arun Srivastava
Journal:  Gastroenterol Clin North Am       Date:  2019-04-01       Impact factor: 3.806

8.  Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.

Authors:  Liujiang Song; M Ariel Kauss; Etana Kopin; Manasa Chandra; Taihra Ul-Hasan; Erin Miller; Giridhara R Jayandharan; Angela E Rivers; George V Aslanidi; Chen Ling; Baozheng Li; Wenqin Ma; Xiaomiao Li; Lourdes M Andino; Li Zhong; Alice F Tarantal; Mervin C Yoder; Kamehameha K Wong; Mengqun Tan; Saswati Chatterjee; Arun Srivastava
Journal:  Cytotherapy       Date:  2013-08       Impact factor: 5.414

9.  A novel and highly efficient AAV6 mutant.

Authors:  Feifei Wang; Can Huang; Jinjing Cao; Xiaomei Liu; Dongxin Wang; Chun Zhang; Qin Chen
Journal:  Virus Genes       Date:  2017-12-27       Impact factor: 2.332

10.  Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants.

Authors:  Damien Marsic; Lakshmanan Govindasamy; Seth Currlin; David M Markusic; Yu-Shan Tseng; Roland W Herzog; Mavis Agbandje-McKenna; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2014-07-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.